Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 amlitelimab in moderate-to-severe atopic dermatitis after prior biologic or oral JAK inhibitor failure
jRCT2061240007Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Proportion of participants with vIGA-AD 0 or 1 and at least 2-point reduction from baseline at Week 36, Proportion of participants reaching EASI-75 at Week 36 and 1 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061240007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240007.